Gerald W. Fischer
EducationLewis and Clark College, Portland, Oregon 1964-1967, Degree - B.A.
University of Oregon Medical School, Portland, Oregon 1967-1971, Degree - M.D.
Pediatric Intern, Madigan Army Medical Center, Tacoma, Washington 1971-1972
Pediatric Resident, Madigan Army Medical Center, Tacoma, Washington 1972-1973
Fellow in Pediatric Infectious Diseases, Tripler Army Medical Center, Honolulu, Hawaii 1973-1975
Pediatric Infectious Disease Fellowship Rotation at SEATO Laboratory/Women's and Children's Hospital, Bangkok, Thailand, 1974
BiographyDr. Gerald Fischer started his Army career in the Senior Medical Student program while getting his M.D. degree at the University of Oregon Medical School and did his pediatric training at Madigan Army Medical Center. He completed his Pediatric Infectious Disease Fellowship at Tripler Army Medical Center, Honolulu, Hawaii in 1975 and he served there as the Assistant Chief, Department of Pediatrics until he came to the Uniformed Services University in 1977 to establish the Pediatric Research Program. He was Director of Pediatric Research and Director of the Pediatric Infectious Disease Fellowship Program. He established the Pediatric HIV Program for the Military in 1988 and was Director of the Program until he retired in 1993 as a Colonel (A prefix) and Professor of Pediatrics. His research has focused on prevention and treatment of neonatal group B streptococcal and staphylococcal sepsis, the use of polyclonal and monoclonal antibodies to prevent or treat infections and rapid diagnosis of infectious diseases to include PCR and gene/genome sequencing. He has authored over 100 papers, and has numerous abstracts, book chapters and patents. He is currently Adjunct Professor of Pediatrics and Senior Advisor to the Pediatric Infectious Diseases Fellowship Program at the Uniformed Services University and Walter Reed National Military Medical Center. Dr. Fischer is the Chairman and CEO of Longhorn Vaccines and Diagnostics, LLC which is focused on utilizing new molecular tools to build better diagnostics, antibodies and vaccines to improve global health. Dr. Fischer is member of many National and International scientific and medical societies. His awards include the Uniformed Services University of the Health Sciences University Medal (No. 7) for Professional and Academic Success, the Armed Forces Infectious Diseases Award, and the Jay P. Sanford Memorial Award for Outstanding Service and Accomplishments in Military Infectious Diseases.
Representative publications, projects, and/or deployments
11. Sei CJ, Daum LT, Schuman RF, Mesadieu A, Rikhi N and Fischer GW. Opsonic Monoclonal Antibodies Directed Against MTB Enhance Blood Clearance in a Quantitative qPCR Mouse Model. Union Meeting, Oct 26-19, 2016.
12. Daum LT, Schuman RF, Sei CJ, Rikhi N, Mesadieu A, Rodriguez JD, Chambers JP, and Fischer GW. Rapid qPCR Detection of Mycobacterium Tuberculosis in Blood and Organ Tissues Using a Collection-to-Detection System. Enliven Archive, Vol. 4, Iss. 1, 2017.
1. Dietzman D, Fischer GW, and Schoentnecht F: Neonatal Escherichia Coli Septicema: Bacterial Counts in Blood. J. Pediatr. 85(1):128-130, 1974.
2. Fischer GW, Balk MW, Crumrine MH, and Bass JW: Immunopotentiation and Antiviral Chemotherapy in a Suckling Rat Model of Herpesvirus Encephalitis. J. Inf. Dis. 133:217, 1976.
3. Fischer GW, Lowell GH, Crumrine M.H, and Bass JW: Demonstration of Opsonic Activity and In vivo Protection Against Group B Streptococci Type III by Streptococcus Pneumonia Type 14 Antisera. J. Exp. Med. 148:776-786, 1978.
4. Hunter KW, Fischer GW, Hemming VG, Wilson SR, Hartzman RJ, and Woody JN: Antibacterial Activity of a Human Monoclonal Antibody to Haemophilus Influenzae Type B Capsular Polysaccharide. Lancet. 2:798-799, 1982.
5. Wear DJ, Margileth AM, Hadfield TL, Fischer GW, Schlagel CJ, and King FM: Cat Scratch Disease: A Bacterial Infection. Science. 221:1403-1405, 1983.
6. Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, Kokai-Kun JF, Mond JJ, Kramer WG and Fischer GW. Phase 1/2 Double Blind Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (Bsyx-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections in Very Low Birth Weight Neonates. Antimicrob Agents Chemother. 53(7):2879-2886, 2009.
7. Daum LT, Rodriguez JD, Worthy SA, Ismail NA, Omar SV, Dreyer AW, Fourie PB, Hoosen AA, Chambers JP, and Fischer GW. Next-Generation Ion Torrent Sequencing of Drug Resistance Mutations in Mycobacterium tuberculosis Strains. J Clin Microbio 50:3831-7, 2012.
8. Daum LT, Choi YW, Worthy SA, Rodriguez JD, Fischer GW, Chambers JP. A Molecular Transport Medium for Collection, Inactivation, Transport, and Detection of Mycobacterium tuberculosis. The International Journal of Tuberculosis and Lung Disease, 18(7):847-9, 2014.
9. Daum LT, Peters RPH, Fourie PB, Jonkman K, Worthy SA, Rodriguez JD, Ismail NA, Omar SV, and Fischer, GW. Molecular Detection of Mycobacterium Tuberculosis from Sputum Transported in PrimeStore from Rural Settings. Int J Tuberc Lung Dis 19(5):552-557, 2015.
10. Daum LT, Fourie PB, Peters RPH, Rodriguez JD, Worthy DA, Khubbar M, Bhattacharyya S, Gradus MS, Mboneni T, Marubini EE, Helm C, Chambers JP and Fischer GW. Xpert MTB/RIF Detection of Mycobacterium Tuberculosis from Sputum Collected in Molecular Transport Medium. Int J Tuberc Lung Dis 20(8):1118-1124, 2016.